Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
Miguel Materin, MD, Director of Ocular Oncology Section, Yale Eye Center, discusses chromosomal analysis within a tumor, the most important guide to clinical survival. Summary: Chromosal analysis of…
NEW YORK (Reuters Health) – The outcome of treatment for early prostate cancer depends on the patient’s sexual, bowel and urinary function at baseline. These factors also influence…
NEW YORK (Reuters Health) – A phase III clinical trial comparing treatments for relapsed or refractory mantle cell lymphoma indicates that temsirolimus (Wyeth Pharmaceuticals, Philadelphia) significantly improves progression-free…
NEW YORK (Reuters Health) – A network of altered genes appears to play a key role in the pathogenesis of gliomas, according to a report in the Journal…
NEW YORK (Reuters Health) – Although capsule endoscopy (PillCam COLON Capsule; Given Imaging) provides visualization of the colonic mucosa, it is not as sensitive as standard colonoscopy for…
A new tool in the fight against Barrett’s Esophagus shows promise. A recent study by Dr. Nicholas Shaheen, director of the University of North Carolina Center for Functional…
NEW YORK (Reuters Health) – Transvaginal sonography (TVS) is superior to symptom analysis for detecting ovarian cancer, while symptom analysis is better able to distinguish benign tumors, according…
NEW YORK (Reuters Health) – New research suggests that regardless of how hormone therapy is given, it increases the risk of ovarian cancer. “Our study suggests an increased…
July 14, 2009 (Portland, Ore.) – One in eight women develop breast cancer in their lifetimes. Although regular mammograms can reduce breast cancer deaths by more than 30…
NEW YORK (Reuters Health) – A further analysis of data from the Women’s Health Initiative (WHI) trials indicates that the risks of hormone therapy still generally outweigh the…
